Johnson & Johnson shares advanced to near their 52-week peak in recent trading, outperforming a broader market pullback driven by escalating Middle East tensions and oil price surges, as investors sought refuge in the healthcare giant’s stable earnings, robust dividend and diversified portfolio.

The company’s stock (NYSE: JNJ) closed at $248.43 on Feb. 27, 2026, up $4.96 or 2.04% from the previous session, on elevated volume of over 16.4 million shares — about 70% above average. In early March 3 trading, shares hovered around $249.24, up modestly in a session where futures indicated pressure from geopolitical risks. The rally pushed JNJ within striking distance of its intraday high of $248.94 from late February, marking a 52-week range from $141.50 to nearly $252. Year-to-date gains exceed 10%, with the stock up about 38% over the past six months despite ongoing talc litigation headwinds.

Johnson & Johnson’s resilience stems from its January 2026 earnings report for the fourth quarter and full year 2025. The company posted strong results, with full-year sales growth supporting an upbeat 2026 outlook. Q4 revenue reached approximately $24.28 billion, while adjusted EPS came in at levels that beat some expectations despite a slight miss in certain views ($2.46 vs. consensus near $2.47). Innovative Medicine (pharmaceuticals) and MedTech segments drove performance, with key products like Darzalex and Tremfya showing robust sales.

For 2026, J&J guided reported sales to $99.5 billion to $100.5 billion (midpoint $100.5 billion, up about 6.7%), and adjusted EPS of $11.43 to $11.63 (midpoint $11.53, up 6.9%). The forecast exceeded Wall Street estimates even after factoring in impacts from drug pricing agreements with the Trump administration and potential tariffs on medical devices, estimated at hundreds of millions. Analysts praised the guidance as conservative yet achievable, highlighting oncology pipeline strength and biosimilar competition offsets.

The company maintains a market capitalization approaching $600 billion, with a forward P/E ratio around 22-23 — viewed as attractive for a blue-chip healthcare name. The quarterly dividend of $1.30 per share (annualized $5.20, yield about 2.09%) remains a draw for income investors. The ex-dividend date was Feb. 24, 2026, with payment on March 10.

Recent pipeline advancements bolster confidence. In late February, J&J reported promising early Phase 1b results for pasritamig (a bispecific T-cell engager) combined with docetaxel in advanced prostate cancer, showing deep PSA reductions and manageable safety. On Feb. 24, the company submitted a supplemental Biologics License Application to the FDA for IMAAVY (nipocalimab) as the first treatment for warm autoimmune hemolytic anemia (wAIHA). Upcoming presentations include the Barclays Global Healthcare Conference on March 10 and TD Cowen on March 3.

Talc litigation continues to cast a shadow, though the stock’s performance suggests investors are pricing in manageable risk. As of early 2026, the multidistrict litigation includes over 67,000 plaintiffs alleging ovarian cancer or mesothelioma from talc products. Recent verdicts include a $250,000 award in a Philadelphia case in February for a deceased user’s family, and larger prior awards like $1.5 billion in a 2025 mesothelioma trial (under appeal). J&J insists its products are safe and asbestos-free, pursuing appeals and settlement discussions. No global resolution has emerged post-bankruptcy attempts.

Analysts maintain a consensus “Moderate Buy” rating, with average price targets around $233 (some as high as $262), implying modest upside or stability from current levels. Firms like Morgan Stanley upgraded to Buy with a $262 target in January, citing improving 2026 prospects.

In a market facing geopolitical uncertainty — with oil surging on Iran-related developments — JNJ’s defensive characteristics shine. Healthcare stocks often hold up during risk-off periods, and J&J’s low beta, consistent cash flow and innovation in high-growth areas like oncology position it well.

The company continues executing its post-Kenvue separation strategy, focusing on Innovative Medicine and MedTech for sustained growth. With next earnings expected around April 14, 2026, investors will watch for updates on pipeline momentum, litigation developments and macro impacts.

Johnson & Johnson’s blend of stability, yield and growth potential keeps it a core holding for many portfolios amid broader volatility.

Verizon Communications Inc. (NYSE: VZ) shares reached a 52-week high in late February 2026, climbing above $50 amid renewed investor confidence in the telecommunications giant’s growth trajectory, subscriber gains and shareholder-friendly capital returns.

The stock closed at $50.14 on Feb. 27, 2026, marking a 2.56% gain for the day and pushing its market capitalization to approximately $211 billion. As of early March trading, shares hovered around $50, with intraday fluctuations between $49.72 and $50.26. The advance represents a significant recovery from the 52-week low of $38.39 hit in late 2025, delivering more than 30% upside over the past year and positioning VZ as a standout performer in the telecom sector.

The rally follows Verizon’s fourth-quarter 2025 earnings report released in late January 2026, which highlighted robust wireless subscriber additions and reaffirmed optimism for the current year. Under new leadership, the company has emphasized cost discipline, network investments and strategic acquisitions to drive sustainable growth.

In the fourth quarter of 2025, Verizon reported total operating revenue of $36.4 billion and adjusted earnings per share of $1.09, excluding special items. The company achieved postpaid phone net additions of 616,000 — the strongest quarterly performance since 2019 — surpassing prior-year figures and beating analyst expectations. Full-year 2025 results included adjusted EPS of $4.71 and capital expenditures of $17 billion, focused primarily on 5G expansion and fiber broadband deployment.

Verizon’s momentum has carried into 2026, supported by guidance that projects adjusted EPS of $4.90 to $4.95, reflecting 4% to 5% growth from 2025 levels. Management anticipates free cash flow expansion of around 7%, bolstered by ongoing subscriber momentum and efficiency initiatives. Analysts project 2026 revenue approaching $144 billion, up more than 4% from the prior year, with EBITDA margins improving to approximately 36.8%.

A key catalyst has been the company’s aggressive capital return strategy. Verizon’s board approved a $25 billion share repurchase program shortly after the new CEO took office, signaling confidence in the stock’s valuation. The company also raised its annual dividend by $0.07 per share — marking the 20th consecutive annual increase — pushing the forward yield to around 5.6% based on the recent $2.83 annualized payout. The ex-dividend date for the upcoming payment is April 10, 2026.

“This is an inflection point for Verizon,” one analyst noted in a February report. “After years of modest growth, the combination of strong wireless adds, broadband expansion and disciplined capital allocation is accelerating EPS and free cash flow.”

The Frontier Communications acquisition, valued at approximately $20 billion and expected to close in stages, has also fueled optimism. Integration efforts are projected to enhance Verizon’s fiber footprint and drive long-term revenue synergies, with some models suggesting potential upside to $68 or higher if subscriber trends and margin improvements materialize.

Verizon’s valuation remains attractive relative to historical averages. Trading at a price-to-earnings ratio of about 12.3 based on trailing earnings of $4.06 per share, the stock appears modestly priced compared with broader market multiples. Its low beta of 0.32 underscores its defensive characteristics, appealing to income-focused investors amid economic uncertainty.

Challenges persist in the competitive telecom landscape. Wireless pricing pressures, legacy business revenue declines and heavy debt levels — with net debt potentially rising toward $190 billion — warrant monitoring. Broadband net additions in recent quarters fell short of some targets, and postpaid phone growth in certain segments like tablets and wearables has been uneven.

Despite these headwinds, Verizon has demonstrated resilience. The company’s 5G network leadership and investments in AI-related services position it to capture emerging demand. Consensus analyst ratings lean toward “Buy,” with average price targets near $49, though some optimistic forecasts envision higher levels if 2026 guidance is met or exceeded.

Investors continue to watch for the next quarterly update, expected around April 21, 2026. With shares trading near all-time highs for the recent cycle, Verizon’s blend of yield, growth acceleration and strategic execution has made it a compelling option for total return seekers in 2026.

Oil prices have climbed after reports that Iranian drones struck a major liquefied natural gas (LNG) facility in Qatar, rattling global energy markets and reigniting debate over energy security.

But while the market reaction was swift, one energy analyst says the United States is structurally better prepared to weather the shock than many of its allies.

“Energy security is national security,” Independent Women’s Center for Energy and Conservation Director Gabriella Hoffman said in an interview with Fox News Digital. “If your energy policy is tied to boosting domestic production and insulating yourself from geopolitical threats, you’re going to be in a stronger position during moments like this.”

In the early morning hours on Saturday, U.S. military forces launched a massive joint military operation against Iran, known as “Operation Epic Fury.” The attacks have already left major leaders dead, including Iranian Supreme Leader Ayatollah Ali Khamenei, and spurred other strikes across the Middle East region.

OIL MARKETS ON EDGE AS IRAN MOVES TO RESTRICT VITAL STRAIT OF HORMUZ SHIPPING LANE, REPORT SAYS

Iranian retaliation involving drone strikes hit energy infrastructure in Qatar on Monday, prompting QatarEnergy to halt LNG production at key facilities. Qatar’s LNG exports account for nearly 20% of global supply.

Early Monday morning, Iranian drones reportedly struck Qatar’s largest oil plant. (Getty Images)

As a result, global benchmark Brent Crude and U.S. crude futures rose sharply, with Brent up more than 8% toward around $79 a barrel and U.S. crude up about 7.6% on Monday amid supply fears.

European energy and natural gas prices also surged in response, underscoring the continent’s continued dependence on imported LNG following its pivot away from Russian gas. Hoffman also noted that major energy importers such as China are significantly reliant on Qatari LNG supplies.

“Countries that are dependent on Middle Eastern reserves are going to have to look closer to home,” Hoffman said. “If you’re relying heavily on foreign suppliers and something like this happens, you’re more exposed to volatility and instability.”

Hoffman argued the United States is less vulnerable than Europe because of its recent surge in domestic production and LNG export capacity. The U.S. recently became the world’s largest net exporter of petroleum products and continues expanding production capacity under Trump administration directives.

That position, she said, provides insulation from external supply shocks.

“We are scaling up production. We’re approving more infrastructure. We’re cutting red tape,” Hoffman said. “If we’re not approving new projects fast enough, that could eventually hold us back.”

Still, she maintained that the U.S. is “in a much stronger position than we would have been” under Biden-Harris policies that constrained domestic production. Hoffman further argued that the Iranian conflict will not fundamentally disrupt American energy goals.

She pointed to prior geopolitical tensions — including developments involving Venezuela — that did not trigger sustained price spikes.

“It’s early,” she cautioned. “We’re still waiting to see how this unfolds. But recent history shows that markets can adjust more quickly than some forecasts suggest.”

“Energy is now a geopolitical tool,” she continued. “If allies see instability from relying on rogue nations or unstable regions, that could increase demand for American LNG.”

GET FOX BUSINESS ON THE GO BY CLICKING HERE

For now, markets remain in a “wait-and-see mode,” according to Hoffman. Much will depend on whether further infrastructure is targeted and whether the conflict escalates.

“We’re sitting on significant proven reserves,” she said. “With the right policies, America can weather this kind of shock… The lesson here… is that energy policy decisions made years ago determine how resilient you are today.”

READ MORE FROM FOX BUSINESS